Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes

Detalhes bibliográficos
Ano de defesa: 2024
Autor(a) principal: Teixeira, Bráulio de Almeida
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal da Paraíba
Brasil
Farmacologia
Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos
UFPB
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: https://repositorio.ufpb.br/jspui/handle/123456789/31946
Resumo: Microorganisms of the Candida genus are responsible for numerous clinical conditions, ranging from localized mycoses such as onychomycosis, oral candidiasis and vulvovaginal candidiasis to systemic mycoses like disseminated candidiasis. Candida spp. are among the primary agents causing death attributed to fungal infections with notable emphasis on species such as Candida albicans, Candida tropicalis, Nakaseomyces glabratus (Candida glabrata) and Candida parapsilosis. These microorganisms are also renowned for their remarkable resistance to antifungal drugs through various mechanisms, including alternative metabolic pathways, biofilm formation, mutations in genes for ergosterol synthesis and overexpression of efflux pumps. The search for new synthetic antifungal molecules represents a therapeutic alternative in this scenario, given the potential for discovering new pharmacological classes or new combined therapy schemes with classical antifungals. In this study, the antifungal profile of a synthetic amide, 2-bromo-N-phenylacetamide, was investigated against C. albicans, C. tropicalis, N. glabratus (C. glabrata) and C. parapsilosis through different assays. 2-bromo-N-phenylacetamide ("A1Br") exhibited fungicidal activity with a Minimum Inhibitory Concentration (MIC) of 32 μg.mL-1 for 87.5% of the tested strains and a Minimum Fungicidal Concentration (MFC) of 64 μg.mL-1 for 81.25% of the microorganisms. It also proved to be a potent agent against mature biofilms of C. albicans with a reduction ranging from 59-80%, statistically as significant as that of amphotericin B (reduction of 32-83%) when comparing each of these treatments to the control group. When combined with the licensed antifungals fluconazole and amphotericin B the molecule "A1Br" exhibited indifferent effects. Its mechanism of action remains to be elucidated since no changes were observed in its MIC in sorbitol and ergosterol assays.
id UFPB-2_900ec6bc57514189ff8f494e99cb3ffb
oai_identifier_str oai:repositorio.ufpb.br:123456789/31946
network_acronym_str UFPB-2
network_name_str Repositório Institucional da UFPB
repository_id_str
spelling Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentesFungicidasCandida spp.BiofilmeAtividade antifúngicaResistência fúngicaFungicidesBiofilmAntifungal activityFungal resistanceCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIAMicroorganisms of the Candida genus are responsible for numerous clinical conditions, ranging from localized mycoses such as onychomycosis, oral candidiasis and vulvovaginal candidiasis to systemic mycoses like disseminated candidiasis. Candida spp. are among the primary agents causing death attributed to fungal infections with notable emphasis on species such as Candida albicans, Candida tropicalis, Nakaseomyces glabratus (Candida glabrata) and Candida parapsilosis. These microorganisms are also renowned for their remarkable resistance to antifungal drugs through various mechanisms, including alternative metabolic pathways, biofilm formation, mutations in genes for ergosterol synthesis and overexpression of efflux pumps. The search for new synthetic antifungal molecules represents a therapeutic alternative in this scenario, given the potential for discovering new pharmacological classes or new combined therapy schemes with classical antifungals. In this study, the antifungal profile of a synthetic amide, 2-bromo-N-phenylacetamide, was investigated against C. albicans, C. tropicalis, N. glabratus (C. glabrata) and C. parapsilosis through different assays. 2-bromo-N-phenylacetamide ("A1Br") exhibited fungicidal activity with a Minimum Inhibitory Concentration (MIC) of 32 μg.mL-1 for 87.5% of the tested strains and a Minimum Fungicidal Concentration (MFC) of 64 μg.mL-1 for 81.25% of the microorganisms. It also proved to be a potent agent against mature biofilms of C. albicans with a reduction ranging from 59-80%, statistically as significant as that of amphotericin B (reduction of 32-83%) when comparing each of these treatments to the control group. When combined with the licensed antifungals fluconazole and amphotericin B the molecule "A1Br" exhibited indifferent effects. Its mechanism of action remains to be elucidated since no changes were observed in its MIC in sorbitol and ergosterol assays.Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPqCoordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESOs microrganismos do gênero Candida são responsáveis por muitas entidades clínicas, envolvendo desde micoses localizadas a exemplo das onicomicoses, candidíases bucais e vulvovaginais a micoses sistêmicas como a candidíase disseminada. As espécies do gênero Candida estão entre os principais agentes responsáveis por óbitos cuja causa seja a infecção por fungos e merecem destaque Candida albicans, Candida tropicalis, Nakaseomyces glabratus (Candida glabrata) e Candida parapsilosis. Tais microrganismos também são lembrados por sua notável capacidade de resistência às drogas antifúngicas através de diversos mecanismos, a saber: vias metabólicas alternativas, formação de biofilmes, mutações nos genes para síntese de ergosterol e superexpressão de bombas de efluxo. A busca por novas moléculas antifúngicas sintéticas constitui-se como uma alternativa terapêutica neste cenário dada a possibilidade da descoberta de novas classes farmacológicas ou de novos esquemas de terapia combinada com os antifúngicos clássicos. Neste estudo foi investigado através de diferentes ensaios o perfil antifúngico de uma amida sintética, a 2-bromo-N-fenilacetamida, frente às espécies C. albicans, C. tropicalis, N. glabratus (C. glabrata) e C. parapsilosis. A molécula 2-bromo-N-fenilacetamida (“A1Br”) exibiu atividade fungicida, com Concentração Inibitória Mínima (CIM) de 32 μg.mL-1 para 87,5% das cepas testadas e Concentração Fungicida Mínima (CFM) de 64 μg.mL-1 para 81,25% dos microrganismos. Também se mostrou um potente agente contra biofilmes maduros de C. albicans, cuja redução variou de 59-80%, estatisticamente tão significativa quanto a da anfotericina B (redução de 32-83%) na comparação de cada um desses tratamentos em relação ao grupo controle. Já quando associada aos antifúngicos licenciados fluconazol e anfotericina B a molécula “A1Br” exibiu efeitos indiferentes. Seu mecanismo de ação permanece passível de esclarecimento uma vez que não foram observadas alterações na sua CIM nos ensaios de sorbitol e ergosterol.Universidade Federal da ParaíbaBrasilFarmacologiaPrograma de Pós-Graduação em Produtos Naturais e Sintéticos BioativosUFPBLima, Edeltrudes de Oliveirahttp://lattes.cnpq.br/9406572870167006Teixeira, Bráulio de Almeida2024-09-20T10:36:49Z2024-04-052024-09-20T10:36:49Z2024-02-23info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttps://repositorio.ufpb.br/jspui/handle/123456789/31946porAttribution-NoDerivs 3.0 Brazilhttp://creativecommons.org/licenses/by-nd/3.0/br/info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFPBinstname:Universidade Federal da Paraíba (UFPB)instacron:UFPB2024-09-21T06:06:29Zoai:repositorio.ufpb.br:123456789/31946Repositório InstitucionalPUBhttps://repositorio.ufpb.br/oai/requestdiretoria@ufpb.br||bdtd@biblioteca.ufpb.bropendoar:25462024-09-21T06:06:29Repositório Institucional da UFPB - Universidade Federal da Paraíba (UFPB)false
dc.title.none.fl_str_mv Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes
title Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes
spellingShingle Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes
Teixeira, Bráulio de Almeida
Fungicidas
Candida spp.
Biofilme
Atividade antifúngica
Resistência fúngica
Fungicides
Biofilm
Antifungal activity
Fungal resistance
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
title_short Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes
title_full Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes
title_fullStr Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes
title_full_unstemmed Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes
title_sort Atividades antibiofilme e fungicida de 2-bromo-n-fenilacetamida frente a Candida spp. fluconazol-resistentes
author Teixeira, Bráulio de Almeida
author_facet Teixeira, Bráulio de Almeida
author_role author
dc.contributor.none.fl_str_mv Lima, Edeltrudes de Oliveira
http://lattes.cnpq.br/9406572870167006
dc.contributor.author.fl_str_mv Teixeira, Bráulio de Almeida
dc.subject.por.fl_str_mv Fungicidas
Candida spp.
Biofilme
Atividade antifúngica
Resistência fúngica
Fungicides
Biofilm
Antifungal activity
Fungal resistance
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
topic Fungicidas
Candida spp.
Biofilme
Atividade antifúngica
Resistência fúngica
Fungicides
Biofilm
Antifungal activity
Fungal resistance
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
description Microorganisms of the Candida genus are responsible for numerous clinical conditions, ranging from localized mycoses such as onychomycosis, oral candidiasis and vulvovaginal candidiasis to systemic mycoses like disseminated candidiasis. Candida spp. are among the primary agents causing death attributed to fungal infections with notable emphasis on species such as Candida albicans, Candida tropicalis, Nakaseomyces glabratus (Candida glabrata) and Candida parapsilosis. These microorganisms are also renowned for their remarkable resistance to antifungal drugs through various mechanisms, including alternative metabolic pathways, biofilm formation, mutations in genes for ergosterol synthesis and overexpression of efflux pumps. The search for new synthetic antifungal molecules represents a therapeutic alternative in this scenario, given the potential for discovering new pharmacological classes or new combined therapy schemes with classical antifungals. In this study, the antifungal profile of a synthetic amide, 2-bromo-N-phenylacetamide, was investigated against C. albicans, C. tropicalis, N. glabratus (C. glabrata) and C. parapsilosis through different assays. 2-bromo-N-phenylacetamide ("A1Br") exhibited fungicidal activity with a Minimum Inhibitory Concentration (MIC) of 32 μg.mL-1 for 87.5% of the tested strains and a Minimum Fungicidal Concentration (MFC) of 64 μg.mL-1 for 81.25% of the microorganisms. It also proved to be a potent agent against mature biofilms of C. albicans with a reduction ranging from 59-80%, statistically as significant as that of amphotericin B (reduction of 32-83%) when comparing each of these treatments to the control group. When combined with the licensed antifungals fluconazole and amphotericin B the molecule "A1Br" exhibited indifferent effects. Its mechanism of action remains to be elucidated since no changes were observed in its MIC in sorbitol and ergosterol assays.
publishDate 2024
dc.date.none.fl_str_mv 2024-09-20T10:36:49Z
2024-04-05
2024-09-20T10:36:49Z
2024-02-23
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://repositorio.ufpb.br/jspui/handle/123456789/31946
url https://repositorio.ufpb.br/jspui/handle/123456789/31946
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv Attribution-NoDerivs 3.0 Brazil
http://creativecommons.org/licenses/by-nd/3.0/br/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NoDerivs 3.0 Brazil
http://creativecommons.org/licenses/by-nd/3.0/br/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade Federal da Paraíba
Brasil
Farmacologia
Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos
UFPB
publisher.none.fl_str_mv Universidade Federal da Paraíba
Brasil
Farmacologia
Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos
UFPB
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFPB
instname:Universidade Federal da Paraíba (UFPB)
instacron:UFPB
instname_str Universidade Federal da Paraíba (UFPB)
instacron_str UFPB
institution UFPB
reponame_str Repositório Institucional da UFPB
collection Repositório Institucional da UFPB
repository.name.fl_str_mv Repositório Institucional da UFPB - Universidade Federal da Paraíba (UFPB)
repository.mail.fl_str_mv diretoria@ufpb.br||bdtd@biblioteca.ufpb.br
_version_ 1863379084710510592